These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 17192459)

  • 1. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.
    Raun K; von Voss P; Gotfredsen CF; Golozoubova V; Rolin B; Knudsen LB
    Diabetes; 2007 Jan; 56(1):8-15. PubMed ID: 17192459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus.
    Vedtofte L; Bodvarsdottir TB; Gotfredsen CF; Karlsen AE; Knudsen LB; Heller RS
    Regul Pept; 2010 Feb; 160(1-3):106-14. PubMed ID: 20005262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.
    Larsen PJ; Fledelius C; Knudsen LB; Tang-Christensen M
    Diabetes; 2001 Nov; 50(11):2530-9. PubMed ID: 11679431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
    Inaba W; Mizukami H; Kamata K; Takahashi K; Tsuboi K; Yagihashi S
    Eur J Pharmacol; 2012 Sep; 691(1-3):297-306. PubMed ID: 22820107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vildagliptin and caloric restriction for cardioprotection in pre-diabetic rats.
    Tanajak P; Pintana H; Siri-Angkul N; Khamseekaew J; Apaijai N; Chattipakorn SC; Chattipakorn N
    J Endocrinol; 2017 Feb; 232(2):189-204. PubMed ID: 27875248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.
    Harder H; Nielsen L; Tu DT; Astrup A
    Diabetes Care; 2004 Aug; 27(8):1915-21. PubMed ID: 15277417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet.
    Apaijai N; Pintana H; Chattipakorn SC; Chattipakorn N
    Endocrinology; 2012 Aug; 153(8):3878-85. PubMed ID: 22621958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
    Breitschaft A; Hu K; Hermosillo Reséndiz K; Darstein C; Golor G
    Diabetes Res Clin Pract; 2014 Mar; 103(3):458-65. PubMed ID: 24461109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase-4 inhibitor enhances restoration of salivary glands impaired by obese-insulin resistance.
    Ittichaicharoen J; Apaijai N; Tanajak P; Sa-Nguanmoo P; Chattipakorn N; Chattipakorn S
    Arch Oral Biol; 2018 Jan; 85():148-153. PubMed ID: 29073562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats.
    Cummings BP; Stanhope KL; Graham JL; Baskin DG; Griffen SC; Nilsson C; Sams A; Knudsen LB; Raun K; Havel PJ
    Diabetes; 2010 Oct; 59(10):2653-61. PubMed ID: 20622169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.
    Flock G; Baggio LL; Longuet C; Drucker DJ
    Diabetes; 2007 Dec; 56(12):3006-13. PubMed ID: 17717280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.
    Mul JD; Begg DP; Barrera JG; Li B; Matter EK; D'Alessio DA; Woods SC; Seeley RJ; Sandoval DA
    Am J Physiol Regul Integr Comp Physiol; 2013 Jul; 305(1):R68-77. PubMed ID: 23616105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
    Edgerton DS; Johnson KM; Neal DW; Scott M; Hobbs CH; Zhang X; Duttaroy A; Cherrington AD
    Diabetes; 2009 Jan; 58(1):243-9. PubMed ID: 18840785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of endogenous glucagon-like peptide-1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetes.
    Xie C; Wang X; Jones KL; Horowitz M; Sun Z; Little TJ; Rayner CK; Wu T
    Diabetes Obes Metab; 2020 Mar; 22(3):383-392. PubMed ID: 31693275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and β-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet.
    Sato K; Nakamura A; Shirakawa J; Muraoka T; Togashi Y; Shinoda K; Orime K; Kubota N; Kadowaki T; Terauchi Y
    Endocrinology; 2012 Mar; 153(3):1093-102. PubMed ID: 22315446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs.
    Raun K; von Voss P; Knudsen LB
    Obesity (Silver Spring); 2007 Jul; 15(7):1710-6. PubMed ID: 17636089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How do different GLP-1 mimetics differ in their actions?
    Choukem SP; Gautier JF
    Curr Diab Rep; 2006 Nov; 6(5):365-72. PubMed ID: 17076997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2007 Apr; 62(4):217-21. PubMed ID: 17566392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats.
    Hansen G; Jelsing J; Vrang N
    Acta Pharmacol Sin; 2012 Feb; 33(2):194-200. PubMed ID: 22301859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.